Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-3-16
pubmed:abstractText
A prospective phase II study was initiated to assess the response rate, survival, and late effects of treatment in patients with newly diagnosed CNS germ cell tumors (GCT), using etoposide plus cisplatin followed by radiation therapy prescribed by extent of disease, histology, and response to chemotherapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
933-40
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:10071287-Adolescent, pubmed-meshheading:10071287-Adult, pubmed-meshheading:10071287-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10071287-Central Nervous System Neoplasms, pubmed-meshheading:10071287-Child, pubmed-meshheading:10071287-Chorionic Gonadotropin, pubmed-meshheading:10071287-Cisplatin, pubmed-meshheading:10071287-Combined Modality Therapy, pubmed-meshheading:10071287-Etoposide, pubmed-meshheading:10071287-Female, pubmed-meshheading:10071287-Germinoma, pubmed-meshheading:10071287-Hematologic Diseases, pubmed-meshheading:10071287-Humans, pubmed-meshheading:10071287-Male, pubmed-meshheading:10071287-Prospective Studies, pubmed-meshheading:10071287-Radiotherapy Dosage, pubmed-meshheading:10071287-Remission Induction, pubmed-meshheading:10071287-Vomiting, pubmed-meshheading:10071287-alpha-Fetoproteins
pubmed:year
1999
pubmed:articleTitle
Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.
pubmed:affiliation
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA. buckner.jan@mayo.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II